Compare Boston Scientific Corporation (BSX) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Raymond James Financial, Inc. — how do they compare? Boston Scientific Corporation trades at $51.56 (market cap $74.19B), while Raymond James Financial, Inc. trades at $180.45 (market cap $34.63B). The key difference: Boston Scientific Corporation is far larger — about 2.1× Raymond James Financial, Inc.'s market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | RJF | |
|---|---|---|
Market Cap | $74.19B | $34.63B |
Sector | Health | Financials |
52-Week High | $108.14 | $180.55 |
52-Week Low | $42.63 | $140.89 |
Enterprise Value | $86.27B | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Raymond James Financial (RJF) trades at $179.09, up 1.43% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows consistent revenue growth, reaching $13.84B in 2025, and a solid net income margin of 15.37%. Recent news highlights record Q3 2026 revenues and strategic acquisitions as key growth drivers.
The outlook is positive with a consensus price target of $183.75, though risks include market volatility and execution of growth initiatives. The stock presents an opportunity based on fundamental strength and analyst support, balanced by the need to monitor expense management and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
